← Leaderboards
Christopher M Counter
Duke University
$20,733,700
Attributed
$20,827,784
Total exposure
18
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.8M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,323,501 · 19
By mechanism
R01$14,633,570 · 6
U54$6,495,717 · 1
P01$3,236,590 · 1
R21$2,104,023 · 6
OT2$501,649 · 1
P30$194,146 · 2
Top collaborators
- Corinne Mary Linardic5 shared
- James L Abbruzzese1 shared
Most similar at Duke University
Same institution · by research overlap
- Donita C Brady$4,868,613
- Zahra Kabiri$395,565
- Dennis J Thiele$8,979,250
- Seth Zimmerman$61,610
Others in their field
Top investigators on “Tumorigenesis”
- Scott W Lowe · Sloan-Kettering Inst Can Research$31,953,893
- Andrea Califano · Columbia University Health Sciences$29,337,086
- Pier Paolo Pandolfi · Sloan-Kettering Institute For Cancer Res$29,078,016
- Piotr Sicinski · Dana-Farber Cancer Inst$23,348,940
- Dario C. Altieri · Wistar Institute$22,047,659
- Eric C Holland · Sloan-Kettering Institute For Cancer Res$21,298,636
Research focus
TumorigenesisMalignant NeoplasmsCellsMutationOncogenicTumorGenesSignal TransductionMutateMolecularProteinsGrowthTumor GrowthMutantPathway InteractionsTumorigenicClinically RelevantBaseKras2 GeneMediatingMalignant Neoplasm Of PancreasCancer TherapyFosteringCancer Cell
Grant awards (86)
Genetic dissection of oncogenic RAS-driven tumor initiation in vivo$442,103
R01 · FY2025 · CA · contact PI
Shared Resource Management$33,056
P30 · FY2025 · CA · contact PI
Genetic dissection of oncogenic RAS-driven tumor initiation in vivo$409,159
R01 · FY2024 · CA · contact PI
Adapting K-MDS to detect KRAS-mutant ctDNA$214,513
R21 · FY2024 · CA · contact PI
PROMINENT-DUKE$34,733
OT2 · FY2024 · CA · contact PI
Genetic dissection of oncogenic RAS-driven tumor initiation in vivo$468,413
R01 · FY2023 · CA · contact PI
PROMINENT-DUKE$238,338
OT2 · FY2023 · CA · contact PI
Adapting K-MDS to detect KRAS-mutant ctDNA$184,406
R21 · FY2023 · CA · contact PI
Proteasomal recruiters of PAX3-FOXO1 Designed via Sequence-Based Generative Models$157,719
U54 · FY2023 · CA
Genetic dissection of oncogenic RAS-driven tumor initiation in vivo$498,229
R01 · FY2022 · CA · contact PI
Screening for Cys-Reactive Ligands to Target PAX3-FOXO1$369,418
U54 · FY2022 · CA
PROMINENT-DUKE$228,578
OT2 · FY2022 · CA · contact PI
Adapting K-MDS to detect KRAS-mutant ctDNA$188,169
R21 · FY2022 · CA · contact PI
Project 4: The role of codon bias in RAS tumorigenesis$667,732
P01 · FY2020 · CA · contact PI
Defining and targeting the molecular vulnerabilities of the PAX3-FOXO1 protein in rhabdomyosarcoma$80,500
U54 · FY2020 · CA
Defining and targeting the molecular vulnerabilities of the PAX3-FOXO1 protein in rhabdomyosarcoma$38,133
U54 · FY2020 · CA
Defining and targeting the molecular vulnerabilities of the PAX3-FOXO1 protein in rhabdomyosarcoma$5,849,947
U54 · FY2019 · CA
Project 4: The role of codon bias in RAS tumorigenesis$552,353
P01 · FY2019 · CA · contact PI
The role of dietary copper in melanoma$352,801
R01 · FY2019 · CA · contact PI
Project 4: The role of codon bias in RAS tumorigenesis$665,328
P01 · FY2018 · CA · contact PI
The role of dietary copper in melanoma$363,713
R01 · FY2018 · CA · contact PI
Dynamic requirements of Ras signaling during cancer$341,774
R01 · FY2018 · CA · contact PI
RalA signal transduction$276,126
R01 · FY2018 · CA · contact PI
Project 4: The role of codon bias in RAS tumorigenesis$664,123
P01 · FY2017 · CA · contact PI
The role of dietary copper in melanoma$363,713
R01 · FY2017 · CA · contact PI
Dynamic requirements of Ras signaling during cancer$341,999
R01 · FY2017 · CA · contact PI
RalA signal transduction$276,126
R01 · FY2017 · CA · contact PI
Project 4: The role of codon bias in RAS tumorigenesis$687,054
P01 · FY2016 · CA · contact PI
The role of dietary copper in melanoma$363,713
R01 · FY2016 · CA · contact PI
Dynamic requirements of Ras signaling during cancer$342,220
R01 · FY2016 · CA · contact PI
RalA signal transduction$276,126
R01 · FY2016 · CA · contact PI
The effect of oncogenic Ras signaling strength on cancer$200,452
R01 · FY2016 · CA · contact PI
The role of dietary copper in melanoma$363,713
R01 · FY2015 · CA · contact PI
Dynamic requirements of Ras signaling during cancer$342,436
R01 · FY2015 · CA · contact PI
RalA signal transduction$275,311
R01 · FY2015 · CA · contact PI
The effect of oncogenic Ras signaling strength on cancer$200,452
R01 · FY2015 · CA · contact PI
Dynamic requirements of Ras signaling during cancer$342,648
R01 · FY2014 · CA · contact PI
RalA signal transduction$263,824
R01 · FY2014 · CA · contact PI
Reducing dietary copper for the treatment of BRaf mutation-positive melanoma$198,738
R21 · FY2014 · CA · contact PI
The effect of oncogenic Ras signaling strength on cancer$194,438
R01 · FY2014 · CA · contact PI
Cancer Biology$43,618
P30 · FY2014 · CA · contact PI
The effect of oncogenic Ras signaling strength on cancer$200,452
R01 · FY2013 · CA · contact PI
Reducing dietary copper for the treatment of BRaf mutation-positive melanoma$170,738
R21 · FY2013 · CA · contact PI
Evaluating the impact of KRas codon bias on pancreatic cancer$73,790
R03 · FY2013 · CA · contact PI
Cancer Biology$26,661
P30 · FY2013 · CA · contact PI
Small molecular weight eNOS inhibitors for the treatment of pancreatic cancer$204,885
R21 · FY2012 · CA · contact PI
Evaluating the impact of KRas codon bias on pancreatic cancer$78,500
R03 · FY2012 · CA · contact PI
Cancer Biology$28,375
P30 · FY2012 · CA · contact PI
Cancer Biology$2,501
P30 · FY2012 · CA · contact PI
Dynamic requirements of Ras signaling during cancer$420,122
R01 · FY2011 · CA · contact PI
Molecular Mechanisms of Neoplastic Transformation in Human Cells$250,570
R01 · FY2011 · CA · contact PI
Small molecular weight eNOS inhibitors for the treatment of pancreatic cancer$170,738
R21 · FY2011 · CA · contact PI
Molecular Mechanisms of Neoplastic Transformation in Human Cells$85,014
R01 · FY2011 · CA · contact PI
Cancer Biology$28,796
P30 · FY2011 · CA · contact PI
Dynamic requirements of Ras signaling during cancer$296,400
R01 · FY2010 · CA · contact PI
Molecular Mechanisms of Neoplastic Transformation in Human Cells$258,320
R01 · FY2010 · CA · contact PI
Preclinical evaluation of NOS inhibitors for the treatment of pancreatic cancer$205,920
R21 · FY2010 · CA · contact PI
Dynamic requirements of Ras signaling during cancer$136,742
R01 · FY2010 · CA · contact PI
Molecular Mechanisms of Neoplastic Transformation in Human Cells$74,834
R01 · FY2010 · CA · contact PI
Cancer Biology$31,139
P30 · FY2010 · CA · contact PI
Dynamic requirements of Ras signaling during cancer$296,400
R01 · FY2009 · CA · contact PI
The Molecular Basis of Telomerase Function & Regulation$295,691
R01 · FY2009 · CA · contact PI
Molecular Mechanisms of Neoplastic Transformation in Human Cells$258,320
R01 · FY2009 · CA · contact PI
Preclinical evaluation of NOS inhibitors for the treatment of pancreatic cancer$171,600
R21 · FY2009 · CA · contact PI
Dynamic requirements of Ras signaling during cancer$296,400
R01 · FY2008 · CA · contact PI
The Molecular Basis of Telomerase Function & Regulation$295,691
R01 · FY2008 · CA · contact PI
Molecular Mechanisms of Neoplastic Transformation in Human Cells$258,320
R01 · FY2008 · CA · contact PI
Developing inhibitors of RalA function for the treatment of pancreatic cancer$187,200
R21 · FY2008 · CA · contact PI
Dynamic requirements of Ras signaling during cancer$296,400
R01 · FY2007 · CA · contact PI
The Molecular Basis of Telomerase Function & Regulation$295,691
R01 · FY2007 · CA · contact PI
Molecular Mechanisms of Neoplastic Transformation in Human Cells$258,320
R01 · FY2007 · CA · contact PI
Developing inhibitors of RalA function for the treatment of pancreatic cancer$155,834
R21 · FY2007 · CA · contact PI
The Molecular Basis of Telomerase Function & Regulation$304,521
R01 · FY2006 · CA · contact PI
Mechanisms of Neoplastic Transformation in Human Cells$250,008
R01 · FY2006 · CA · contact PI
The Molecular Basis of Telomerase Function &Regulation$311,850
R01 · FY2005 · CA
Mechanisms of Neoplastic Transformation in Human Cells$256,025
R01 · FY2005 · CA
Mechanisms of Neoplastic Transformation in Human Cells$256,025
R01 · FY2004 · CA
MECHANISMS OF NEOPLASTIC TRANSFORMATION IN HUMAN CELLS$5,516
P51 · FY2004 · RR
TELOMERASE FUNCTION AND REGULATION$318,686
R01 · FY2003 · CA
Mechanisms of Neoplastic Transformation in Human Cells$256,025
R01 · FY2003 · CA
Targetting Functional Domains in Telomerase$25,641
R21 · FY2003 · CA
TELOMERASE FUNCTION AND REGULATION$309,443
R01 · FY2002 · CA
Mechanisms of Neoplastic Transformation in Human Cells$256,025
R01 · FY2002 · CA
Targetting Functional Domains in Telomerase$25,641
R21 · FY2002 · CA
TELOMERASE FUNCTION AND REGULATION$299,666
R01 · FY2001 · CA
TELOMERASE FUNCTION AND REGULATION$242,120
R01 · FY2000 · CA